Advertisement

June 26, 2020

Abbott’s LightLab Initiative Shows OCT Imaging Changes Coronary Treatment Decisions

June 26, 2020—Abbott announced that the first data reported from the company’s LightLab Initiative showed that optical coherence tomography (OCT) imaging significantly changes how physicians decide to treat a vessel (compared to traditional angiography) by providing physicians improved visualization within a patient’s blood vessels. The findings were presented as part of the virtual three-day PCR e-Course held by the European Association of Percutaneous Cardiovascular Interventions online from June 25-27.

According to the company, the new data provide strong evidence of the value of using OCT for decision-making within the PCI procedure. Initial data found the following:

  • OCT changed angiographic-based decisions in 88% of lesions in coronary arteries.
  • After deploying a stent, physicians made changes in treating 31% of lesions based on OCT information to treat damage to the artery previously invisible with angiography alone.
  • Physicians improved their assessment of potential blockages as a result of using OCT, which better informed the choice of stent size and optimal stent deployment compared with angiography alone.

Abbott noted that OCT uses laser technology to capture high-resolution images inside a patient’s arteries, displaying the type and severity of disease in the vessel and enabling more accurate measurements to determine how the patient should be treated.

The LightLab Initiative was designed to examine the role and impact of OCT on physician decision-making, procedural efficiency, and procedural safety over angiography during procedures for patients with vascular disease.

Abbott collaborated with interventional cardiologists in 12 medical centers across the United States and collected PCI procedural data over a 12-month period. Of the 2,203 procedures and 1,016 interventions assessed in the first phase of the LightLab Initiative, physicians used OCT before and after stenting in 652 lesions.

The level of detail and the volume of data collected in this real-world patient cohort demonstrates the impact of OCT on lesion assessment, procedural planning, and stent optimization. Further analyses from subsequent phases of the program are planned in the coming months.

The subsequent phases of the LightLab Initiative will focus on optimizing the prescribed treatment steps when using OCT to achieve greater efficiency (shorter timing) and safety with lower contrast and radiation exposure gains, thereby identifying and removing barriers to OCT adoption.

“After planning a procedure with angiography alone, we exposed physicians to all the information provided by OCT on the same blockage and were able to demonstrate the significant impact that the information had on our decisions,” commented Hiram Bezerra, MD, in the company’s announcement. “OCT takes the guesswork out of angiography, offering doctors real-time high-quality granularity and precision when performing PCIs and helping doctors make real-time decisions in the cath lab.” Dr. Bezerra is Professor of Medicine at the University of South Tampa and the Director of Cardiac Interventional Services at Tampa General Hospital in Tampa, Florida.

Advertisement


June 29, 2020

Interim Data Reported From the First-in-Human MOCA I Trial of CorFlow's CoFI System

June 25, 2020

Medtronic’s Global SYMPLICITY Registry Shows Sustained Lower Blood Pressure After Renal Denervation